MedWatch

Analyst: New Genmab approval shows portfolio potential

The approval of the drug Tivdak, which is developed by Genmab and its partner Seagen, is in many ways a milestone achievement for the Danish biotech company, explains Senior Analyst at Sydbank Søren Løntoft Hansen.

Photo: Tuala Hjarnø / Genmab / PR

This isn't the first approval of a Genmab-developed drug, nor is it the first cancer drug that the Danish biotech company is behind. Nonetheless, the approval of tisotumab vedotin, under the commercial name Tivdak, by the US Food and Drug Administration (FDA) is an important stepping stone on the path forward, says Søren Løntoft Hansen, senior analyst at Sydbank.

"The approval of Tivdak is very positive in the way it contributes to the gradually growing portfolio of approved medicines coming from Genmab laboratories, which emphasizes that Genmab is now more than just Darzalex," he tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs